Skip to main content
. 2024 Nov 4;16(21):3712. doi: 10.3390/cancers16213712

Figure 4.

Figure 4

Overall survival of patients receiving the combination therapy of ICIs and (A) chemotherapy and (B) anti-CTLA-4 antibodies as first-line therapy in serum CYFRA 21-1 level. Time is expressed in months.